AOD-9604 occupies a regulatory gray zone with no lawful route to human use in the United States. It is a synthetic fragment of human growth hormone that has never earned FDA approval, does not meet the statutory definition of a dietary supplement ingredient, and was declined for pharmacy compounding, so its sale rests entirely on the ambiguous "research use" framing rather than any affirmative clearance.
AOD-9604 is neither an FDA-approved medicine, a legal dietary supplement, nor an endorsed compounding ingredient, leaving no lawful path to human use in the United States.
No approval exists, and the confusion usually traces back to AOD-9604's real clinical history rather than any regulatory status it holds. The peptide reached Phase II human trials as an anti-obesity candidate in the 2000s, but those studies did not beat placebo convincingly, the obesity program was discontinued before Phase III, and having been tested under an investigational new drug framework is not the same as being approved.
| Criteria | Investigational status | FDA approval |
|---|---|---|
| What it means | Permission to test in humans under a controlled protocol | Agency finding that a drug is safe and effective for a labeled use |
| AOD-9604's position | Reached Phase II obesity trials, then discontinued | Never granted for any indication |
| Legal identity for use | None outside the trial protocol | Authorized product for the labeled indication |
AOD-9604 advanced to Phase II obesity trials under an investigational new drug framework but was never granted FDA approval for obesity, joint repair, or any other indication.
It does not, and the reason is a specific statutory test rather than a judgment about the molecule's effects. A lawful dietary ingredient must be a vitamin, mineral, herb, amino acid, or a concentrate or metabolite of one, and it must clear the law's exclusionary clause; AOD-9604 fails on both counts, which is why supplement-style packaging carries no legal weight.
The dietary supplement exclusionary clause bars any ingredient first investigated as a drug with public clinical trials, which captures AOD-9604 and makes no product containing it a lawful supplement.
Compounding was the most plausible legitimate channel through which a patient might obtain a peptide that lacks its own drug approval, and the FDA closed it. Reviewing AOD-9604 as a bulk drug substance under Section 503A, the agency declined to add it to the permitted list, so no pharmacy can lawfully rely on that route to prepare and dispense it.
The FDA reviewed AOD-9604 as a bulk drug substance and declined to place it on the Section 503A list, removing any sanctioned pharmacy compounding pathway.
The ban holds independently of any government's approval decision. Growth hormone fragments fall within the World Anti-Doping Agency's category for peptide hormones, growth factors, and mimetics, a class prohibited at all times, so an athlete gains nothing from the argument that AOD-9604 is a partial sequence rather than full-length hGH.
AOD-9604 is banned for tested athletes at all times under the World Anti-Doping Agency's peptide-hormone and growth-factor category, and strict liability means the "research chemical" label offers no defense.
The "research chemical" or "not for human consumption" line is a seller's liability disclaimer, not a mark of legitimacy or a genuine legal exemption. Regulators judge a product by its intended use across the totality of its marketing, so dosing calculators, injection guides, and bacteriostatic water sold alongside the vials tend to defeat the disclaimer rather than protect it.
The "research chemical" disclaimer is a legal fig leaf that neither makes the sale lawful nor guarantees the vial's purity, identity, or dosing accuracy.
Outside the United States the substance of the picture is the same even where the specific rules differ: no major national medicines regulator has approved AOD-9604, so it stands as an unapproved substance almost everywhere it is sold. Many countries fold peptides like it into prescription-only or unapproved-medicine frameworks, so supplying or possessing an injectable version without authorization can breach medicines law even without a compound-specific listing.
No major national medicines regulator has approved AOD-9604, and most jurisdictions capture it through general prescription-only or unapproved-medicine rules rather than a compound-specific ban.
Sellers carry the heavier legal exposure, and it runs well beyond what the "research chemical" framing suggests. A vendor marketing AOD-9604 for human effects is offering an unapproved, misbranded drug, while an individual buyer's realistic risk is less about criminal prosecution and more about receiving an unverified injectable with no recourse.
| Criteria | Sellers | Buyers |
|---|---|---|
| Legal characterization | Marketing an unapproved, misbranded drug | Personal-use possession, rarely prosecuted |
| Typical enforcement | Warning letters, injunctions, seizures, possible criminal referral | Customs seizure with no recourse |
| Practical risk | Escalating FDA action once claims are documented | Unverified injectable with no quality assurance |
Sellers marketing AOD-9604 for human use face FDA warning letters, seizures, and possible criminal referral, while buyers mainly risk seized shipments and an unverified injectable rather than prosecution.
Educational use only. This article describes what the published scientific and clinical literature reports about AOD-9604. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
